16 completed, 7 unknown, 6 terminated, 4 recruiting. 25 Phase 1, 13 Phase 2, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 9, Unknown 7, Recruiting 4, Terminated 4, Active not recruiting 1 |
| Phase 2 | 13 | Completed 10, Terminated 3 |
| Not applicable | 3 | Completed 3 |
Follow Indium: new trials by email Literature Review of Indium trials Research Report on Indium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-07-31 |
| Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 40 | 2023-10-03 | 2025-10-03 |
| Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer Panitumumab, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography - Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2023-08-22 | 2026-03-05 |
| Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Actinium Ac 225-DOTA-Daratumumab, Daratumumab, Indium In 111-DOTA-Daratumumab - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2022-11-22 | 2025-10-29 |
| 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 7 | 2022-07-19 | 2026-07-06 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 3 | 2017-02-01 | 2020-11-23 |
| Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine - Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 | Completed | Fred Hutchinson Cancer Center | 16 | 2012-01-01 | 2019-12-10 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan rituximab, fludarabine phosphate, melphalan - Graft Versus Host Disease, Leukemia | Phase 2 | Completed | City of Hope Medical Center | 41 | 2007-10-03 | 2024-02-16 |
| Absorptive Clearance in the Cystic Fibrosis Airway Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA - Cystic Fibrosis | Not applicable | Completed | University of Pittsburgh | 21 | 2007-10-01 | 2017-08-24 |
| Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 Sorafenib, 111Indium-bevacizumab, 111Indium-cG250 - Clear Cell Renal Cell Carcinoma | Not applicable | Completed | Radboud University Medical Center | 26 | 2007-07-01 | 2013-12-02 |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma rituximab, prednisone, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Terminated | National Cancer Institute (NCI) | 62 | 2004-12-01 | 2017-05-25 |
| Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis - Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 / Phase 2 | Completed | Mayo Clinic | 38 | 2004-10-01 | 2016-02-04 |
| Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes - Lymphoma, Small Intestine Cancer | Completed | Mayo Clinic | 17 | 2003-09-01 | 2017-03-22 | |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan - Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2003-07-01 | 2013-01-25 |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma darbepoetin alfa, filgrastim, rituximab - Lymphoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 65 | 2003-02-10 | 2020-11-12 |
| Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan - AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2002-06-01 | 2013-01-17 |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma rituximab, yttrium Y 90 ibritumomab tiuxetan, indium In 111 ibritumomab tiuxetan - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 81 | 2001-04-01 | 2018-08-09 |
| Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy filgrastim, monoclonal antibody m170, cyclosporine - Prostate Cancer | Phase 1 | Unknown | University of California, Davis | 2001-03-01 | 2013-09-20 | |
| Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma monoclonal antibody Lym-1, cyclosporine, paclitaxel - Lymphoma | Phase 1 | Unknown | University of California, Davis | 2001-03-01 | 2013-09-20 |
Showing 20 of 34. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, B-Cell, Marginal Zone (12) · Burkitt Lymphoma (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Follicular (11) · Lymphoma, Mantle-Cell (10) · Lymphoma, Non-Hodgkin (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Lymphoma (9) · Waldenstrom Macroglobulinemia (9) · Lymphoma, Large-Cell, Immunoblastic (7) · Leukemia (4) · Leukemia, Myeloid, Acute (3) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2)
Garden State Cancer Center at the Center for Molecular Medicine and Immunology (8) · City of Hope Medical Center (4) · Fred Hutchinson Cancer Center (4) · National Cancer Institute (NCI) (4) · University of California, Davis (4) · Mayo Clinic (2) · Vanderbilt-Ingram Cancer Center (2) · Cancer Research Institute of Contra Costa (1) · Endocyte (1) · Memorial Sloan Kettering Cancer Center (1) · Radboud University Medical Center (1) · University of Alabama at Birmingham (1) · University of Pittsburgh (1)
United States (33) · Netherlands (1)
Jack D. Burton, MD (8) · Ajay Gopal (3) · Thomas Witzig (3) · Eben Rosenthal, MD (2) · Gerald L. DeNardo, MD (2) · Jeffrey Y Wong (2) · Brenda Sandmaier (1) · Carol M. Richman, MD (1) · David M. Gershenson, MD (1) · David Scadden (1) · Gregory Wiseman, MD (1) · Mansoor N Saleh, MD (1) · Matthew Mei, MD (1) · Michael M. Graham, PhD, MD (1) · Mitchell Cairo (1)
PMID 19717485, PMID 20956472, PMID 27009167, PMID 31582553, PMID 37301631, PMID 38698840, PMID 41498537
P01CA044991 (4), P30CA015704 (4), P30CA033572 (3), R01CA067026 (2), P01CA030206 (1), P01CA054425 (1), P30CA015083 (1), R01CA266233 (1), R03CA077146 (1), U01CA070019 (1), U01CA097452 (1), U10CA021115 (1)